Additive to the pathway
ImmunoPDT is positioned, initially, as additive to the existing pathway, not a replacement for standard of care. It is studied as a function-preserving option in the early-stage active-surveillance gap, and as a precise, repeatable salvage option after treatment failure. As the evidence base grows, its role in the pathway may broaden over time.
Where ImmunoPDT sits in the pathway.
ImmunoPDT is studied as an additive, function-preserving option within the existing prostate-cancer pathway, not a replacement for standard of care.
Register your interest
Register your interest as a clinician or investigator. We will be in touch about the ImmunoPDT programme.
We use your details only to respond to your enquiry. See our Privacy policy.
Clinical-stage statement. Immuno1 is investigational. ImmunoPDT is a clinical-stage company. The therapy is not approved for marketing in any jurisdiction.
Forward-looking statement. This material contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties. Past clinical results are not a guarantee of future outcomes.